- Novel reversible methionine aminopeptidase-2 (MetAP-2) inhibitors based on purine and related bicyclic templates
-
The natural product fumagillin 1 and derivatives like TNP-470 2 or beloranib 3 bind to methionine aminopeptidase 2 (MetAP-2) irreversibly. This enzyme is critical for protein maturation and plays a key role in angiogenesis. In this paper we describe the synthesis, MetAP-2 binding affinity and structural analysis of reversible MetAP-2 inhibitors. Optimization of enzymatic activity of screening hit 10 (IC50: 1?μM) led to the most potent compound 27 (IC50: 0.038?μM), with a concomitant improvement in LLE from 2.1 to 4.2. Structural analysis of these MetAP-2 inhibitors revealed an unprecedented conformation of the His339 side-chain imidazole ring being co-planar sandwiched between the imidazole of His331 and the aryl-ether moiety, which is bound to the purine scaffold. Systematic alteration and reduction of H-bonding capability of this metal binding moiety induced an unexpected 180° flip for the triazolo[1,5-a]pyrimdine bicyclic template.
- Heinrich, Timo,Buchstaller, Hans-Peter,Cezanne, Bertram,Rohdich, Felix,Bomke, J?rg,Friese-Hamim, Manja,Krier, Mireille,Kn?chel, Thorsten,Musil, Djordje,Leuthner, Birgitta,Zenke, Frank
-
p. 551 - 556
(2017/01/17)
-
- FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS
-
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein X1 , X2, X 3, Y1 , Y 2, R 1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
- -
-
Page/Page column 86-87
(2016/10/24)
-
- NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS
-
Compounds of the formula I, in which D, X, Y, Z, R and R1 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
- -
-
Page/Page column 16-17
(2011/11/30)
-
- THERAPEUTIC AGENTS
-
The invention provides a compound of formula (I): wherein R1, and W have any of the values defined in the application; or a salt thereof. The compounds and salts thereof have beneficial therapeutic properties (e.g. immunosuppressant properties).
- -
-
Page/Page column 47
(2010/04/03)
-